Acute myelogenous leukemia

New drug, new data, new decisions

Research output: Contribution to journalReview article

Abstract

Over the past decade, improvements in the therapy of acute myelogenous leukemia (AML) have focused on the use of new agents in the induction regimen and on intensifying post-remission therapy in an attempt to prolong the duration of complete remission. In induction, the major efforts have been in substituting newer anthracyclines and other agents for daunorubicin and in increasing the dose of cytosine arabinoside (Ara-C) or adding additional agents to induction such as etoposide. These alterations have not significantly improved the complete remission rate but appear to improve remission duration (Weick, et al, 1996; Bishop, et al, 1998). Whether high-dose Ara-C is optimally given in consolidation or in induction is not clear (Bishop, et al, 1998; Mayer, et al, 1994). The issue of intensifying induction therapy in AML has been recently reviewed (Rowe, Tallman, 1997). The focus of this discussion will be on a novel agent that is emerging for the treatment of AML in induction and on the results of the large intergroup trials in the United States and Europe addressing the role of allogeneic and autologous stem cell transplantation as post-remission therapy for AML. For a recent comprehensive overview on the biology and therapy of AML, the reader is referred to an education session at the American Society of Hematology meeting in Miami Beach, Florida, in December 1998 (Appelbaum, et al, 1998).

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalCancer Research, Therapy and Control
Volume11
Issue number2
StatePublished - 2001

Fingerprint

Acute Myeloid Leukemia
Cytarabine
Pharmaceutical Preparations
Therapeutics
Daunorubicin
Anthracyclines
Stem Cell Transplantation
Etoposide
Education

Keywords

  • Acute Myelogenous Leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Acute myelogenous leukemia : New drug, new data, new decisions. / Litzow, Mark R.

In: Cancer Research, Therapy and Control, Vol. 11, No. 2, 2001, p. 99-105.

Research output: Contribution to journalReview article

@article{ffa6f1da30af43e086d7806308a1250b,
title = "Acute myelogenous leukemia: New drug, new data, new decisions",
abstract = "Over the past decade, improvements in the therapy of acute myelogenous leukemia (AML) have focused on the use of new agents in the induction regimen and on intensifying post-remission therapy in an attempt to prolong the duration of complete remission. In induction, the major efforts have been in substituting newer anthracyclines and other agents for daunorubicin and in increasing the dose of cytosine arabinoside (Ara-C) or adding additional agents to induction such as etoposide. These alterations have not significantly improved the complete remission rate but appear to improve remission duration (Weick, et al, 1996; Bishop, et al, 1998). Whether high-dose Ara-C is optimally given in consolidation or in induction is not clear (Bishop, et al, 1998; Mayer, et al, 1994). The issue of intensifying induction therapy in AML has been recently reviewed (Rowe, Tallman, 1997). The focus of this discussion will be on a novel agent that is emerging for the treatment of AML in induction and on the results of the large intergroup trials in the United States and Europe addressing the role of allogeneic and autologous stem cell transplantation as post-remission therapy for AML. For a recent comprehensive overview on the biology and therapy of AML, the reader is referred to an education session at the American Society of Hematology meeting in Miami Beach, Florida, in December 1998 (Appelbaum, et al, 1998).",
keywords = "Acute Myelogenous Leukemia",
author = "Litzow, {Mark R}",
year = "2001",
language = "English (US)",
volume = "11",
pages = "99--105",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Acute myelogenous leukemia

T2 - New drug, new data, new decisions

AU - Litzow, Mark R

PY - 2001

Y1 - 2001

N2 - Over the past decade, improvements in the therapy of acute myelogenous leukemia (AML) have focused on the use of new agents in the induction regimen and on intensifying post-remission therapy in an attempt to prolong the duration of complete remission. In induction, the major efforts have been in substituting newer anthracyclines and other agents for daunorubicin and in increasing the dose of cytosine arabinoside (Ara-C) or adding additional agents to induction such as etoposide. These alterations have not significantly improved the complete remission rate but appear to improve remission duration (Weick, et al, 1996; Bishop, et al, 1998). Whether high-dose Ara-C is optimally given in consolidation or in induction is not clear (Bishop, et al, 1998; Mayer, et al, 1994). The issue of intensifying induction therapy in AML has been recently reviewed (Rowe, Tallman, 1997). The focus of this discussion will be on a novel agent that is emerging for the treatment of AML in induction and on the results of the large intergroup trials in the United States and Europe addressing the role of allogeneic and autologous stem cell transplantation as post-remission therapy for AML. For a recent comprehensive overview on the biology and therapy of AML, the reader is referred to an education session at the American Society of Hematology meeting in Miami Beach, Florida, in December 1998 (Appelbaum, et al, 1998).

AB - Over the past decade, improvements in the therapy of acute myelogenous leukemia (AML) have focused on the use of new agents in the induction regimen and on intensifying post-remission therapy in an attempt to prolong the duration of complete remission. In induction, the major efforts have been in substituting newer anthracyclines and other agents for daunorubicin and in increasing the dose of cytosine arabinoside (Ara-C) or adding additional agents to induction such as etoposide. These alterations have not significantly improved the complete remission rate but appear to improve remission duration (Weick, et al, 1996; Bishop, et al, 1998). Whether high-dose Ara-C is optimally given in consolidation or in induction is not clear (Bishop, et al, 1998; Mayer, et al, 1994). The issue of intensifying induction therapy in AML has been recently reviewed (Rowe, Tallman, 1997). The focus of this discussion will be on a novel agent that is emerging for the treatment of AML in induction and on the results of the large intergroup trials in the United States and Europe addressing the role of allogeneic and autologous stem cell transplantation as post-remission therapy for AML. For a recent comprehensive overview on the biology and therapy of AML, the reader is referred to an education session at the American Society of Hematology meeting in Miami Beach, Florida, in December 1998 (Appelbaum, et al, 1998).

KW - Acute Myelogenous Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0034964009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034964009&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 99

EP - 105

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 2

ER -